Matches in SemOpenAlex for { <https://semopenalex.org/work/W2036930192> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W2036930192 endingPage "S201" @default.
- W2036930192 startingPage "S201" @default.
- W2036930192 abstract "Objective:To characterize the safety and tolerability of desvenlafaxine succinate (DVS) in patients with major depressive disorder (MDD).Methods:Pooled data from 7 double-blind, placebo-controlled studies were analyzed. Adult outpatients with DSM-IV MDD received DVS or placebo for 8 weeks. Four studies employed flexible dosing of DVS (100-200mg/d [1 study]; 200-400mg/d [3 studies]); 3 studies evaluated fixed doses (100/200/400mg/d [1 study]; 200/400mg/d [2 studies]). Vital signs and treatment-emergent adverse events (TEAEs) were evaluated. In the fixed-dose subset of studies, dose-related effects were analyzed.Results:The overall safety population consisted of 2014 patients (DVS: n=1211; placebo: n=803); 60% were women. Adverse events were responsible for discontinuations in 4% of placebo-treated patients and 15% of DVS-treated patients. Discontinuation rates increased with dose (10% with 100mg/d to 17% with 400mg/d) in the subset of fixed-dose studies. TEAEs were consistent with the serotonin-norepinephrine reuptake inhibitor (SNRI) class. Nausea was generally mild to moderate with a median duration less than or = to 6 days; the incidence decreased to placebo-like rates after week 1. With all doses of DVS, small but statistically significant changes in mean blood pressure were observed. Mean changes in pulse rate and the proportion of potentially clinically important increases in sustained elevations in supine diastolic blood pressure were higher for patients receiving 200/400mg/d than among placebo-treated subjects; values for these parameters with the 100mg/d dose did not differ from placebo.Conclusions:DVS treatment exhibited a safety and tolerability profile that was generally consistent with the SNRI class." @default.
- W2036930192 created "2016-06-24" @default.
- W2036930192 creator A5017307477 @default.
- W2036930192 creator A5020995037 @default.
- W2036930192 creator A5027047677 @default.
- W2036930192 creator A5042407610 @default.
- W2036930192 creator A5068545843 @default.
- W2036930192 date "2008-04-01" @default.
- W2036930192 modified "2023-09-23" @default.
- W2036930192 title "Pooled analysis of the safety and tolerability of desvenlafaxine Succinate compared with placebo in the treatment of major depressive disorder" @default.
- W2036930192 doi "https://doi.org/10.1016/j.eurpsy.2008.01.321" @default.
- W2036930192 hasPublicationYear "2008" @default.
- W2036930192 type Work @default.
- W2036930192 sameAs 2036930192 @default.
- W2036930192 citedByCount "2" @default.
- W2036930192 crossrefType "journal-article" @default.
- W2036930192 hasAuthorship W2036930192A5017307477 @default.
- W2036930192 hasAuthorship W2036930192A5020995037 @default.
- W2036930192 hasAuthorship W2036930192A5027047677 @default.
- W2036930192 hasAuthorship W2036930192A5042407610 @default.
- W2036930192 hasAuthorship W2036930192A5068545843 @default.
- W2036930192 hasConcept C118552586 @default.
- W2036930192 hasConcept C126322002 @default.
- W2036930192 hasConcept C142724271 @default.
- W2036930192 hasConcept C15744967 @default.
- W2036930192 hasConcept C197934379 @default.
- W2036930192 hasConcept C204787440 @default.
- W2036930192 hasConcept C27081682 @default.
- W2036930192 hasConcept C2778375690 @default.
- W2036930192 hasConcept C2780051608 @default.
- W2036930192 hasConcept C2780733359 @default.
- W2036930192 hasConcept C71924100 @default.
- W2036930192 hasConceptScore W2036930192C118552586 @default.
- W2036930192 hasConceptScore W2036930192C126322002 @default.
- W2036930192 hasConceptScore W2036930192C142724271 @default.
- W2036930192 hasConceptScore W2036930192C15744967 @default.
- W2036930192 hasConceptScore W2036930192C197934379 @default.
- W2036930192 hasConceptScore W2036930192C204787440 @default.
- W2036930192 hasConceptScore W2036930192C27081682 @default.
- W2036930192 hasConceptScore W2036930192C2778375690 @default.
- W2036930192 hasConceptScore W2036930192C2780051608 @default.
- W2036930192 hasConceptScore W2036930192C2780733359 @default.
- W2036930192 hasConceptScore W2036930192C71924100 @default.
- W2036930192 hasLocation W20369301921 @default.
- W2036930192 hasOpenAccess W2036930192 @default.
- W2036930192 hasPrimaryLocation W20369301921 @default.
- W2036930192 hasRelatedWork W1593963136 @default.
- W2036930192 hasRelatedWork W2061731424 @default.
- W2036930192 hasRelatedWork W2120729007 @default.
- W2036930192 hasRelatedWork W2157547590 @default.
- W2036930192 hasRelatedWork W2418300191 @default.
- W2036930192 hasRelatedWork W2465070206 @default.
- W2036930192 hasRelatedWork W3049243667 @default.
- W2036930192 hasRelatedWork W4251484736 @default.
- W2036930192 hasRelatedWork W4297914005 @default.
- W2036930192 hasRelatedWork W4366364599 @default.
- W2036930192 hasVolume "23" @default.
- W2036930192 isParatext "false" @default.
- W2036930192 isRetracted "false" @default.
- W2036930192 magId "2036930192" @default.
- W2036930192 workType "article" @default.